Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APN401 in advanced solid tumors
NCT02166255Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2014
- Primary completion
- May 2016
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APN401 in melanoma, renal cell carcinoma (RCC), pancreatic cancer (PC) and 1 more, sponsored by Wake Forest University Health Sciences. Primary endpoints: Maximum Tolerated Dose at 14 days, Incidence of Adverse Events up to 2 years and 1 more. Started Dec 2014; status: completed.
02
Drugs
APN401
03
Conditions
melanomarenal cell carcinoma (RCC)pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT02166255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02166255.